Albireo Pharma Inc. buy melinda
Start price
04.04.19
/
50%
€30.49
Target price
04.11.21
€35.00
Performance (%)
-1.61%
End price
01.07.21
€30.00
Summary
This prediction ended on 01.07.21 with a price of €30.00. With a performance of -1.61%, the BUY prediction for Albireo Pharma Inc. by melinda closed slightly in the red. melinda has 50% into this predictionPerformance without dividends (%)
Name | 1w | 1m | 1y | 3y |
---|---|---|---|---|
Albireo Pharma Inc. | - | - | - | - |
iShares Core DAX® | 2.594% | -1.861% | 13.242% | 16.867% |
iShares Nasdaq 100 | 3.553% | -2.064% | 38.293% | 45.898% |
iShares Nikkei 225® | 0.687% | -8.704% | 17.510% | 2.760% |
iShares S&P 500 | 2.209% | -1.988% | 27.632% | 42.955% |
According to melinda what are the pros and cons of Albireo Pharma Inc. for the foreseeable future?
Pros
Could be worthwhile Investment >10% per year
Cons
Comments by melinda for this prediction
In the thread Albireo Pharma Inc. diskutieren
Secteur Recherche biotechnologique et médicale Agenda 16/05 Publication de résultats
Albireo Pharma, Inc., anciennement Biodel Inc, est une société biopharmaceutique spécialisée. Elle se concentre sur le développement et la commercialisation des modulateurs de l'acide biliaire pour traiter les maladies du foie et des troubles gastro-intestinaux (GI) chez les enfants, des problèmes de débit ou d'absorption inadéquate de la bile troubles médicaux graves pour lesquels il existe un besoin. A4250, the cholestase intrahépatique familiale progressive (PFIC). A4250 Fait partie d'un essai clinique de phase II, dont Elobixibat, A3384 et modulateurs of biliaire. Elobixibat est indiqué pour le traitement de la constipation et ses essais cliniques de phase III. A3384 est une formulation de cholestyramine intégrée dans le cholestyramine directement dans le cycle. Elle a terminé un essai clinique de phase II d'une formulation antérieure de A3384 dans la malabsorption des acides biliaires (BAM).
Nombre d'employés
: 22 personnes.
In the thread Trading Albireo Pharma Inc.
Buy beendet
Stopped prediction by melinda for Albireo Pharma Inc.
Albireo Pharma Inc.
Start price
Target price
Perf. (%)
€26.40
12.10.21
12.10.21
€29.00
12.10.22
12.10.22
-15.27%
13.10.22
13.10.22
Could be worthwhile Investment >10% per year
Albireo Pharma Inc.
Start price
Target price
Perf. (%)
€22.55
02.02.19
02.02.19
€29.00
13.03.19
13.03.19
12.55%
13.03.19
13.03.19
Could be worthwhile Investment >10% per year
Albireo Pharma Inc.
Start price
Target price
Perf. (%)
€26.46
08.08.18
08.08.18
€28.86
10.08.18
10.08.18
9.92%
10.08.18
10.08.18
Could be worthwhile Investment >10% per year
Albireo Pharma Inc.
Start price
Target price
Perf. (%)
€30.70
20.04.18
20.04.18
€45.10
10.07.18
10.07.18
7.70%
10.07.18
10.07.18
Could be worthwhile Investment >10% per year
Albireo Pharma Inc.
Start price
Target price
Perf. (%)
€25.28
23.10.17
23.10.17
€27.06
05.01.18
05.01.18
7.88%
05.01.18
05.01.18
Could be worthwhile Investment >10% per year
Albireo Pharma Inc.
Start price
Target price
Perf. (%)
€19.71
15.08.17
15.08.17
€24.81
30.08.17
30.08.17
17.39%
30.08.17
30.08.17
Could be worthwhile Investment >10% per year
Albireo Pharma Inc.
Start price
Target price
Perf. (%)
€21.85
15.08.17
15.08.17
€27.50
30.08.17
30.08.17
17.39%
30.08.17
30.08.17
Could be worthwhile Investment >10% per year
Albireo Pharma Inc.
Start price
Target price
Perf. (%)
€19.21
01.07.17
01.07.17
€19.84
05.07.17
05.07.17
3.47%
05.07.17
05.07.17
Could be worthwhile Investment >10% per year
Albireo Pharma Inc.
Start price
Target price
Perf. (%)
€21.30
01.07.17
01.07.17
€22.00
05.07.17
05.07.17
3.47%
05.07.17
05.07.17
Could be worthwhile Investment >10% per year
Albireo Pharma Inc.
Start price
Target price
Perf. (%)
€364.80
14.10.10
14.10.10
€540.00
14.04.11
14.04.11
-47.70%
14.04.11
14.04.11
Could be worthwhile Investment >10% per year